Phase II Trial of Amsacrine Plus Intermediate-dose Ara-C (IDAC) with or without Etoposide as Salvage Therapy for Refractory or Relapsed Acute Leukemia

Estey E. Treatment of refractory AML. Leukemia1996;10:932–6.

Herzig RH, Lazarus HM, Wolff SN, Phillips GL, Herzig GP. High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia. J Clin Oncol1985;3:992–7.

Welborn JL. Impact of reinduction regimens for relapsed and refractory acute lymphoblastic leukemia in adults. Am J Hematol1994;45:341–4.

Hiddemann W, Kreutzmann H, Straif K, Ludwig WD, Mertelsmann R, Planker M, et al. High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia. Semin Oncol1987;14:73–7.

Hiddemann W, Buchner T, Heil G, Schumacher K, Diedrich H, Maschmeyer G, et al. Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM). Leukemia1990;4:637–40.

Kim DH, Sohn SK, Kim JG, Lee NY, Sung WJ, Baek JH, et al. Parameters for predicting allogeneic PBSCT outcome of acute myeloid leukemia: cytogenetics at presentation versus disease status at transplantation. Ann Hematol2005;84:25–32.

An International System for Human Cytogenetic Nomenclature (1985) ISCN 1985. Report of the Standing Committee on Human Cytogenetic Nomenclature. Birth Defects Orig Artic Ser1985;21:1–117.

Ellison RR, Holland JF, Weil M, Jacquillat C, Boiron M, Bernard J, et al. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood1968;32:507–23.

Preisler HD. Failure of remission induction in acute myelocytic leukemia. Med Pediatr Oncol1978;4:275–6.

Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol2003;13:176–81.

Hann IM, Stevens RF, Goldstone AH, Rees JK, Wheatley K, Gray RG, et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood1997;89:2311–8.

Cain BF, Atwell GJ. The experimental antitumour properties of three congeners of the acridylmethanesulphonanilide (AMSA) series. Eur J Cancer1974;10:539–49.

Legha SS, Keating MJ, Zander AR, McCredie KB, Bodey GP, Freireich EJ. 4′-(9-Acridinylamino) methanesulfon-m-anisidide (AMSA): a new drug effective in the treatment of adult acute leukemia. Ann Intern Med1980;93:17–21.

Arlin ZA, Sklaroff RB, Gee TS, Kempin SJ, Howard J, Clarkson BD, et al. Phase I and II trial of 4′-(9-acridinylamino)methanesulfon-m-anisidide in patients with acute leukemia. Cancer Res1980;40:3304–6.

Weiss RB, Grillo-Lopez AJ, Marsoni S, Posada JG Jr, Hess F, Ross BJ. Amsacrine-associated cardiotoxicity: an analysis of 82 cases. J Clin Oncol1986;4:918–28.

Arlin ZA, Feldman E, Kempin S, Ahmed T, Mittelman A, Savona S, et al. Amsacrine with high-dose cytarabine is highly effective therapy for refractory and relapsed acute lymphoblastic leukemia in adults. Blood1988;72:433–5.

Bradstock KF, Matthews JP, Lowenthal RM, Baxter H, Catalano J, Brighton T, et al. A randomized trial of high versus conventional dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high dose cytarabine. Blood2004;105:481–8.

Dekker AW, Nieuwenhuis HK, Verdonck LF. Intermediate-dose cytosine arabinoside and amsacrine. An effective regimen with low toxicity in refractory acute nonlymphocytic leukemia. Cancer1990;65:1891–4.

Mehta J, Powles R, Singhal S, Horton C, Hamblin M, Zomas A, et al. Idarubicin, high-dose cytarabine, and etoposide for induction of remission in acute leukemia. Semin Hematol1996;33:18–23.

Kimby E, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in acute myeloid leukaemia. Acta Oncol2001;40:231–52.

Raanani P, Shpilberg O, Gillis S, Avigdor A, Hardan I, Berkowicz M, et al. Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabine. Leuk Res1999;23:695–700.

Schiller G. Treatment of resistant acute myeloid leukemia. Blood Rev1991;5:220–6.

Kern W, Schleyer E, Unterhalt M, Wormann B, Buchner T, Hiddemann W. High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study. Cancer1997;79:59–68.

Hines JD, Oken MM, Mazza JJ, Keller AM, Streeter RR, Glick JH. High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia. J Clin Oncol1984;2:545–9.